Antiviral properties of trans-δ-viniferin derivatives against enveloped viruses.
Broad-spectrum antiviral
Influenza virus
SARS-CoV-2
Stilbene dimer derivatives
Virucidal
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
22
02
2023
revised:
19
04
2023
accepted:
30
04
2023
medline:
29
5
2023
pubmed:
7
5
2023
entrez:
6
5
2023
Statut:
ppublish
Résumé
Over the last century, the number of epidemics caused by RNA viruses has increased and the current SARS-CoV-2 pandemic has taught us about the compelling need for ready-to-use broad-spectrum antivirals. In this scenario, natural products stand out as a major historical source of drugs. We analyzed the antiviral effect of 4 stilbene dimers [1 (trans-δ-viniferin); 2 (11',13'-di-O-methyl-trans-δ-viniferin), 3 (11,13-di-O-methyl-trans-δ-viniferin); and 4 (11,13,11',13'-tetra-O-methyl-trans-δ-viniferin)] obtained from plant substrates using chemoenzymatic synthesis against a panel of enveloped viruses. We report that compounds 2 and 3 display a broad-spectrum antiviral activity, being able to effectively inhibit several strains of Influenza Viruses (IV), SARS-CoV-2 Delta and, to some extent, Herpes Simplex Virus 2 (HSV-2). Interestingly, the mechanism of action differs for each virus. We observed both a direct virucidal and a cell-mediated effect against IV, with a high barrier to antiviral resistance; a restricted cell-mediated mechanism of action against SARS-CoV-2 Delta and a direct virustatic activity against HSV-2. Of note, while the effect was lost against IV in tissue culture models of human airway epithelia, the antiviral activity was confirmed in this relevant model for SARS-CoV-2 Delta. Our results suggest that stilbene dimer derivatives are good candidate models for the treatment of enveloped virus infections.
Identifiants
pubmed: 37148860
pii: S0753-3322(23)00615-7
doi: 10.1016/j.biopha.2023.114825
pmc: PMC10158552
pii:
doi:
Substances chimiques
Antiviral Agents
0
delta-viniferin
0
Stilbenes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114825Informations de copyright
Copyright © 2023. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Microorganisms. 2021 Jun 01;9(6):
pubmed: 34205874
J Nat Prod. 2020 Mar 27;83(3):770-803
pubmed: 32162523
Front Plant Sci. 2022 Jan 13;12:805610
pubmed: 35095976
J Virol. 1996 Jun;70(6):4188-92
pubmed: 8648766
Expert Opin Drug Deliv. 2013 Sep;10(9):1287-302
pubmed: 23730924
J Biomol Struct Dyn. 2021 Jun;39(9):3099-3114
pubmed: 32329408
Nat Mater. 2018 Feb;17(2):195-203
pubmed: 29251725
Sci Rep. 2019 Dec 20;9(1):19525
pubmed: 31862939
Crit Care Res Pract. 2010;2010:
pubmed: 20948883
J Nat Prod. 2017 Apr 28;80(4):887-898
pubmed: 28332842
Acta Pharm Sin B. 2016 May;6(3):243-52
pubmed: 27175336
Mar Drugs. 2010 Oct 11;8(10):2619-38
pubmed: 21116410
J Nat Prod. 2020 Aug 28;83(8):2347-2356
pubmed: 32705864
Adv Sci (Weinh). 2020 Dec 14;8(3):2001012
pubmed: 33552848
Front Chem. 2022 Apr 19;10:881298
pubmed: 35518712
Sci Rep. 2021 Jul 12;11(1):14295
pubmed: 34253743
AAPS J. 2021 Jan 5;23(1):14
pubmed: 33400058
J Virol. 2018 May 14;92(11):
pubmed: 29563290
J Virol. 2007 Nov;81(22):12439-49
pubmed: 17855549
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
PLoS Pathog. 2018 Aug 3;14(8):e1007190
pubmed: 30075025
Commun Biol. 2022 Oct 10;5(1):1075
pubmed: 36216966
Sci Rep. 2020 Jul 22;10(1):12523
pubmed: 32694540
Science. 2009 Jul 10;325(5937):161-5
pubmed: 19589993
J Allergy Clin Immunol. 2018 Jun;141(6):2074-2084
pubmed: 28797733
Expert Rev Anti Infect Ther. 2010 Jun;8(6):635-8
pubmed: 20521891
Front Chem. 2022 May 31;10:912396
pubmed: 35711965